Equities

Bajaj Healthcare Ltd

BAJAJHCARE:NSI

Bajaj Healthcare Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)378.40
  • Today's Change-6.70 / -1.74%
  • Shares traded137.90k
  • 1 Year change-12.41%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024 11:26 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in INRIncome statement in INRView more

Year on year Bajaj Healthcare Ltd's revenues fell -26.69% from 6.46bn to 4.73bn. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from a gain of 430.24m to a loss of 837.93m.
Gross margin48.43%
Net profit margin-2.80%
Operating margin1.40%
Return on assets--
Return on equity--
Return on investment--
More ▼

Cash flow in INRView more

In 2024, cash reserves at Bajaj Healthcare Ltd fell by 155.46m. However, the company earned 922.94m from its operations for a Cash Flow Margin of 19.50%. In addition the company used 112.45m on investing activities and also paid 965.96m in financing cash flows.
Cash flow per share5.34
Price/Cash flow per share82.84
Book value per share--
Tangible book value per share--
More ▼

Balance sheet in INRView more

Bajaj Healthcare Ltd uses little or no debt in its capital structure.
Current ratio--
Quick ratio--
Total debt/total equity--
Total debt/total capital--
More ▼

Growth rates in INR

Year on year, growth in dividends per share remained flat while earnings per share excluding extraordinary items fell by -122.55%.
Div yield(5 year avg)0.22%
Div growth rate (5 year)--
Payout ratio (TTM)--
EPS growth(5 years)--
EPS (TTM) vs
TTM 1 year ago
-122.70
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.